Synplogen, founded in 2017, is a rising player in the Biopharma and Biotechnology sectors. Their approach leverages over a decade of advancements in genetic engineering, information science, and robotics, primarily developed by Kobe University and other contributors. This unique integration enables Synplogen to offer cutting-edge solutions in high-throughput DNA synthesis, positioning them as pioneers in the field.
Their compelling slogan, "Pioneering advanced DNA synthesis with a decade of innovation in genetic engineering, information science, and robotics for high-throughput results," reflects their commitment to innovation and leadership in advanced synthetic biology techniques. The latest investment activity was a Venture Round on November 30, 2021, with participation from i-nest capital, highlighting continued investor interest and confidence in the company's growth potential.
